Buy Diaper Bank raffle ticket, win stay in a fancy inn, help families in need of diapers
The Athens Area Diaper Bank is hosting its annual Spring Getaway Raffle to benefit their work of distributing diapers to families in need in the local community.
The prizes this year include a two-night stay and $150 food/beverage credit for Chateau Elan in Braselton or a one-night stay at the new Athenian Inn in downtown Athens. Tickets are $20 each or 3 for $50.
The winners will be drawn on May 24. Funds raised from the raffle will be used to purchase and distribute diapers to families in need.
Life in Athens: Southern charm and lively arts: Why Athens ranks as a top-100 place to live in the U.S.
This is the third year for the raffle.
Anyone interested in learning more or purchasing tickets can go to the homepage at www.athensareadiaperbank.com.
Each month, Athens Area Diaper Bank distributes 65,000 diapers to families in a six-county area that includes Barrow, Clarke, Jackson, Madison, Oconee and Oglethorpe. The warehouse operation is located at 130 Conway Drive in Bogart.
This article originally appeared on Athens Banner-Herald: Athens Area Diaper Bank selling tickets to 3rd annual spring raffle
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Bloomberg
36 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
Gizmodo
36 minutes ago
- Gizmodo
Musk Deletes His ‘Really Big Bomb' Claiming Trump Appears in Epstein Files
In the middle of their very public breakup, a scorned Elon Musk decided to drop a 'really big bomb' on Donald Trump, accusing the president of appearing in the Epstein files. Sometime Saturday, it seems the billionaire decided he wanted to try to disarm that bomb, as he deleted his posts claiming that Trump has links to the famous child sex trafficker. Musk and Trump had been acting catty for a couple of days by the time Musk went nuclear, going back and forth over Musk's opposition to Trump's 'Big Beautiful Bill'—a proposal that includes the largest cuts to Medicaid and food assistance programs in history. Musk objected to the bill, but not because it would be devastating to low- and middle-income households, but seemingly rather because it was going to hurt his own bottom line by ending electric vehicle tax credits that Tesla benefits from. Musk tried to kill the bill by posting incessantly about it, creating a rift among Republicans who will essentially need everyone in the party to be on board in order to get the thing passed. Trump, annoyed, took some shots at Musk for his dissent, which led to Musk just blowing the whole thing up. He said Trump appeared in the Epstein files and 'That is the real reason they have not been made public.' Funnily, he also doubled down by saying, 'Mark this post for the future. The truth will come out.' Those posts are now deleted—though have, of course, been archived, screenshotted, and quoted many times over. So, too, has a post in which Musk supported the idea that Trump should be impeached. He hasn't gotten around to taking down his post claiming that Trump's tariffs will cause a recession, so, it's clear the two aren't fully ready to make up, even if there is a de-escalation. We're also starting to get more of a picture of what has been happening behind the scenes while these two air out each other in public. A report published Saturday by the Washington Post claims that Trump was 'dejected' during Musk's crash out, and tried to rationalize Musk's behavior by calling him 'a big-time drug addict.' Musk had apparently been acting erratically for quite some time (not exactly a shock if you've scrolled through his posts on Twitter for like, 30 seconds), and a reported physical conflict with Treasury Secretary Scott Bessent that saw Musk supposedly throw his shoulder into Bessent was the breaking point where the billionaire started to get pushed out, per the Post. Trump opted not to pour gasoline on the situation—a shocking decision from a guy not exactly known for his restraint—but also is apparently not interested in reconciling with Musk. An official within the administration told the Post that even if they do make up, 'It'll never be the same.'
